Original Query: ALL
Previous Study | Return to List | Next Study

Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00598312
Recruitment Status : Completed
First Posted : January 21, 2008
Last Update Posted : September 8, 2010
Information provided by:
Oakwood Laboratories, LLC

Brief Summary:
The purpose of the study is to demonstrate the safety and efficacy of Leuprolide Acetate for Injectable Suspension 22.5 mg in reducing serum testosterone to castrate levels in patients with prostate cancer.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: Leuprolide Acetate for Injectable Suspension Phase 3

Detailed Description:
This study is an open-label, multi-center study in which a minimum of 165 patients will receive one (1) of three (3) lots of Oakwood Laboratories' Leuprolide Acetate for Injectable Suspension 22.5 mg for two cycles. A subset of patients (minimum of 12) will be assigned to each lot (A, B or C) and will have additional blood sampling to characterize leuprolide release kinetics for each dose administered.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 201 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, Open-Label, Multi-Center, Safety And Efficacy Study of Oakwood Laboratories' Leuprolide Acetate For Injectable Suspension 22.5 mg In Patients With Prostate Cancer
Study Start Date : April 2007
Primary Completion Date : August 2008
Study Completion Date : August 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
U.S. FDA Resources

Intervention Details:
    Drug: Leuprolide Acetate for Injectable Suspension
    Sustained release injectable microspheres, 22.5 mg, one injection every 84 days, 3-month product

Primary Outcome Measures :
  1. The percentage of responders who attain and maintain castrate levels of serum testosterone [ Time Frame: From Day 28 to Day 168. ]

Secondary Outcome Measures :
  1. Safety as shown through laboratory parameters [ Time Frame: Day 0 - Day 168 ]
    Hematology, chemistry and urinalysis

  2. Leuprolide serum profiles following administration study drug product. [ Time Frame: Day 0 - Day 168 ]
    Leuprolide levels (ng/dL) measured at designated time points to determine a pharmacokinetic profile for the product.

  3. Safety as shown through reported adverse events [ Time Frame: Day 0 -168 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   45 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Reads, understands and is able and willing to sign informed consent form
  • Males greater than or equal to age 45
  • Histologically and cytologically documented prostate carcinoma
  • Candidate for initial hormone therapy - inclusive of patients beginning neoadjuvant or intermittent therapy, being treated locally for advanced disease, or patients beginning therapy for failure of prior local therapy
  • Patients who have had prior LHRH therapy in an adjuvant or neoadjuvant setting, providing that the last date of effective therapy was greater than 6 months prior to screening
  • ECOG 0-2
  • Morning serum testosterone level > 150 ng/dL
  • Standard screening labs within 2x ULN (AST, ALT, bilirubin and serum creatinine)
  • Hemoglobin > 10 g/dL
  • Life expectancy of >1yr.
  • Willing to complete both cycles and all procedures of the study

Exclusion Criteria:

  • Any prior (except for prior LHRH therapy in an adjuvant or neoadjuvant setting) or current definitive therapy for prostate cancer, including chemotherapy, immunotherapy, tumor-vaccines,biological response modifiers, or estrogens
  • Patients who have undergone any prostatic surgery within 4 weeks of Baseline
  • Patients who have undergone orchiectomy, adrenalectomy, or hypophysectomy
  • Patients that are currently hospitalized or require frequent hospitalization
  • Prior resistance to LHRH therapy, either neoadjuvant or adjuvant.
  • Patients with evidence of spinal cord compression, ureteral obstruction or clinically significant bladder outlet obstruction
  • Participation in any investigational drug, biologic, or device study within five half-lives of its physiological action or three months prior to enrollment, whichever was longer
  • Patients anticipated to need concomitant hormonal, anti-androgen, radio-, chemo-, immuno- or surgical therapy for prostate cancer while on study
  • History of recent drug and/or alcohol abuse within 6 months of screening
  • History of HIV, HCV or HBV infection
  • History of hypersensitivity or known allergy to LHRH agonists or antagonists
  • Concurrent use of daily corticosteroids or other agents known to modify serum androgen within 12 weeks of screening visit
  • Patients on other anti-androgens such as flutamide, nilutamide or bicalutamide
  • History of other cancer with the exception of non-metastatic basal or squamous cell carcinoma of the skin
  • Patients receiving any type of 5-alpha reductase inhibitor such as Proscar, Propecia, or Avodart within the past 3 months
  • Patients who have experienced a myocardial infarction, unstable or uncontrolled cardiovascular disease or a coronary vascular procedure within 6 months of Baseline
  • Patients who have experienced venous thrombosis within 6 months of Baseline
  • Patients with other serious intercurrent illness(es) or disease(s)that might interfere with, or put them at additional risk for, their ability to receive the treatment outlined in the protocol
  • Patients who have a history of the following: Immunization within 4 weeks of Baseline; Flu shots within 2 weeks of Baseline; Donation or receipt of blood or blood products within 2 months of Baseline; Anaphylaxis
  • Patients who have received Oakwood's leuprolide acetate formulation previously.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00598312

United States, Ohio
Oakwood Laboratories, LLC
Oakwood Village, Ohio, United States, 44146
Sponsors and Collaborators
Oakwood Laboratories, LLC
Principal Investigator: Daniel Saltzstein, MD Urology San Antonio Research PA
Study Chair: James Page, MD Oakwood Laboratories, LLC
Study Director: Beth Glasgow Oakwood Laboratories, LLC

Responsible Party: Edward C. Smith, Chairman, Oakwood Laboratories, LLC Identifier: NCT00598312     History of Changes
Other Study ID Numbers: OL-01110
First Posted: January 21, 2008    Key Record Dates
Last Update Posted: September 8, 2010
Last Verified: September 2010

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents